No­var­tis bur­nish­es prospects for its big asth­ma drug with pos­i­tive PhI­II da­ta from a sim­i­lar treat­ment

No­var­tis has some good news to share on the asth­ma front as it sets the scene for a block­buster Phase III read­out.

The star to­day is low dose QMF149, a com­bo of the long-act­ing be­ta ag­o­nist (LA­BA) in­da­caterol ac­etate and the cor­ti­cos­teroid mometa­sone furoate. The once-dai­ly in­hala­tion beat a cor­ti­cos­teroid monother­a­py on all pri­ma­ry and sec­ondary end­points, in­clud­ing forced ex­pi­ra­to­ry vol­ume and asth­ma con­trol as mea­sured by a ques­tion­naire.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.